191 related articles for article (PubMed ID: 31841972)
1. Generation of a GLA knock-out human-induced pluripotent stem cell line, KSBCi002-A-1, using CRISPR/Cas9.
Kim YK; Yu JH; Min SH; Park SW
Stem Cell Res; 2020 Jan; 42():101676. PubMed ID: 31841972
[TBL] [Abstract][Full Text] [Related]
2. Generation of a CRISPR/Cas9-corrected-hiPSC line (DDLABi001-A) from Fabry disease (FD)-derived iPSCs having α-galactosidase (GLA) gene mutation (c.803_806del).
Choi JB; Seo D; Do HS; Han YM
Stem Cell Res; 2023 Feb; 66():103001. PubMed ID: 36516658
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9-mediated A4GALT suppression rescues Fabry disease phenotypes in a kidney organoid model.
Cui S; Shin YJ; Fang X; Lee H; Eum SH; Ko EJ; Lim SW; Shin E; Lee KI; Lee JY; Lee CB; Bae SK; Yang CW; Chung BH
Transl Res; 2023 Aug; 258():35-46. PubMed ID: 36805562
[TBL] [Abstract][Full Text] [Related]
4. Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells.
Do HS; Park SW; Im I; Seo D; Yoo HW; Go H; Kim YH; Koh GY; Lee BH; Han YM
EBioMedicine; 2020 Feb; 52():102633. PubMed ID: 31981984
[TBL] [Abstract][Full Text] [Related]
5. Generation of human induced pluripotent stem cell line MHHi029-A from a male Fabry disease patient carrying c.959A > T mutation.
Jahn C; Juchem M; Sonnenschein K; Gietz A; Buchegger T; Lachmann N; Göhring G; Behrens YL; Bär C; Thum T; Hoepfner J
Stem Cell Res; 2024 Jun; 77():103404. PubMed ID: 38552356
[TBL] [Abstract][Full Text] [Related]
6. Using CRISPR/Cas9-Mediated GLA Gene Knockout as an In Vitro Drug Screening Model for Fabry Disease.
Song HY; Chiang HC; Tseng WL; Wu P; Chien CS; Leu HB; Yang YP; Wang ML; Jong YJ; Chen CH; Yu WC; Chiou SH
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27983599
[TBL] [Abstract][Full Text] [Related]
7. Human kidney organoids reveal the role of glutathione in Fabry disease.
Kim JW; Kim HW; Nam SA; Lee JY; Cho HJ; Kim TM; Kim YK
Exp Mol Med; 2021 Oct; 53(10):1580-1591. PubMed ID: 34654880
[TBL] [Abstract][Full Text] [Related]
8. Generation of
Song HY; Chien CS; Yarmishyn AA; Chou SJ; Yang YP; Wang ML; Wang CY; Leu HB; Yu WC; Chang YL; Chiou SH
Cells; 2019 Apr; 8(4):. PubMed ID: 30965672
[TBL] [Abstract][Full Text] [Related]
9. Generation of Fabry cardiomyopathy model for drug screening using induced pluripotent stem cell-derived cardiomyocytes from a female Fabry patient.
Kuramoto Y; Naito AT; Tojo H; Sakai T; Ito M; Shibamoto M; Nakagawa A; Higo T; Okada K; Yamaguchi T; Lee JK; Miyagawa S; Sawa Y; Sakata Y; Komuro I
J Mol Cell Cardiol; 2018 Aug; 121():256-265. PubMed ID: 30048710
[TBL] [Abstract][Full Text] [Related]
10. Characterization and phosphoproteomic analysis of a human immortalized podocyte model of Fabry disease generated using CRISPR/Cas9 technology.
Pereira EM; Labilloy A; Eshbach ML; Roy A; Subramanya AR; Monte S; Labilloy G; Weisz OA
Am J Physiol Renal Physiol; 2016 Nov; 311(5):F1015-F1024. PubMed ID: 27681560
[TBL] [Abstract][Full Text] [Related]
11. Dissociation of globotriaosylceramide and impaired endothelial function in α-galactosidase-A deficient EA.hy926 cells.
Kaissarian N; Kang J; Shu L; Ferraz MJ; Aerts JM; Shayman JA
Mol Genet Metab; 2018 Dec; 125(4):338-344. PubMed ID: 30413389
[TBL] [Abstract][Full Text] [Related]
12. Human-induced pluripotent stem cell lines (CMCi006-A and CMCi007-A) from a female and male patient with Fabry disease carrying the same frameshift deletion mutation.
Cui S; Shin YJ; Ko EJ; Lim SW; Ju JH; Lee KI; Lee JY; Yang CW; Chung BH
Stem Cell Res; 2021 Mar; 51():102214. PubMed ID: 33545641
[TBL] [Abstract][Full Text] [Related]
13. Reversal of the Inflammatory Responses in Fabry Patient iPSC-Derived Cardiovascular Endothelial Cells by CRISPR/Cas9-Corrected Mutation.
Song HY; Yang YP; Chien Y; Lai WY; Lin YY; Chou SJ; Wang ML; Wang CY; Leu HB; Yu WC; Chien CS
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33673551
[TBL] [Abstract][Full Text] [Related]
14. Generation of GLA-knockout human embryonic stem cell lines to model peripheral neuropathy in Fabry disease.
Kaneski CR; Hanover JA; Schueler Hoffman UH
Mol Genet Metab Rep; 2022 Dec; 33():100914. PubMed ID: 36092250
[TBL] [Abstract][Full Text] [Related]
15. Generation of the induced pluripotent stem cell line UKWNLi005-A derived from a patient with the GLA mutation c.376A > G of unknown pathogenicity in Fabry disease.
Breyer M; Klein T; Klug K; Klopocki E; Üçeyler N
Stem Cell Res; 2022 May; 61():102747. PubMed ID: 35325818
[TBL] [Abstract][Full Text] [Related]
16. Proteomic analysis unveils Gb3-independent alterations and mitochondrial dysfunction in a gla
Elsaid HOA; Rivedal M; Skandalou E; Svarstad E; Tøndel C; Birkeland E; Eikrem Ø; Babickova J; Marti HP; Furriol J
J Transl Med; 2023 Sep; 21(1):591. PubMed ID: 37670295
[TBL] [Abstract][Full Text] [Related]
17. α-galactosidase A deficiency promotes von Willebrand factor secretion in models of Fabry disease.
Kang JJ; Kaissarian NM; Desch KC; Kelly RJ; Shu L; Bodary PF; Shayman JA
Kidney Int; 2019 Jan; 95(1):149-159. PubMed ID: 30470436
[TBL] [Abstract][Full Text] [Related]
18. Generation of 'designer erythroblasts' lacking one or more blood group systems from CRISPR/Cas9 gene-edited human-induced pluripotent stem cells.
Pandey P; Zhang N; Curtis BR; Newman PJ; Denomme GA
J Cell Mol Med; 2021 Oct; 25(19):9340-9349. PubMed ID: 34547166
[TBL] [Abstract][Full Text] [Related]
19. Generation of human induced pluripotent stem cell line carrying SCN5AC2204>T Brugada mutation (MUSli009-A-1) introduced by CRISPR/Cas9-mediated genome editing.
Angsutararux P; Luanpitpong S; Chingsuwanrote P; Supraditaporn K; Waeteekul S; Terbto P; Lorthongpanich C; Laowtammathron C; U-Pratya Y; Issaragrisil S
Stem Cell Res; 2019 Dec; 41():101618. PubMed ID: 31677524
[TBL] [Abstract][Full Text] [Related]
20. Generation of two homozygous SHOX2 knock-out human induced pluripotent stem cell lines using CRISPR/Cas9.
Rädecke K; Gore A; Burau K; Laugsch M; Köhler K; Rappold GA; Hoffmann S
Stem Cell Res; 2023 Jun; 69():103089. PubMed ID: 37028180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]